aTyr Pharma, Inc. (ATYR) vs Aytu BioPharma, Inc. (AYTU)
A side-by-side comparison of aTyr Pharma, Inc. and Aytu BioPharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ATYR
aTyr Pharma, Inc.
$0.29HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
AYTU
Aytu BioPharma, Inc.
$2.04HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — ATYR vs AYTU
growth of $100 · dividends reinvested · last 2yATYR -83.2% (-59.1%/yr)AYTU -32.1% (-17.6%/yr)AYTU compounded faster over this window
ATYR AYTU
ATYR vs AYTU: by the numbers
- •ATYR is the larger company ($28M vs $22M market cap).
- •Both run net losses; AYTU's is the smaller (-24.76% vs -32003.68% net margin).
- •Both shrank revenue over the past five years; AYTU's decline was smaller (-2.59% vs -38.74% CAGR).
Metrics side by side
Valuation
| Metric | ATYR | AYTU |
|---|---|---|
| P/S ratio | 149.66 | 0.38 |
| P/B ratio | 0.58 | 0.62 |
| FCF yield | N/A | 14.85% |
Profitability
| Metric | ATYR | AYTU |
|---|---|---|
| Gross margin | -717.37% | 63.95% |
| Operating margin | -40856.32% | -14.44% |
| Net margin | -32003.68% | -24.76% |
| ROE | -124.64% | -40.40% |
| ROIC | -109.29% | -14.21% |
Growth (annualized)
| Metric | ATYR | AYTU |
|---|---|---|
| Revenue CAGR (5Y) | -38.74% | -2.59% |
| Total return CAGR (5Y) | N/A | -48.14% |
Frequently asked
- Which has grown faster, ATYR or AYTU?
- Neither grew: over the past five years both shrank revenue, with AYTU's decline the smaller — ATYR at a -38.74% CAGR versus AYTU at -2.59%.
Go deeper
Dig into the metrics
aTyr Pharma ROEAytu BioPharma ROEaTyr Pharma operating marginAytu BioPharma operating marginaTyr Pharma revenue growthAytu BioPharma revenue growthaTyr Pharma free cash flowAytu BioPharma free cash flow
aTyr Pharma & Aytu BioPharma appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.